Federal Reserve's Williams: Bond purchases expected to start soon
BlockBeats News, November 8, Federal Reserve's Williams stated on Friday that the Fed decided last week to stop reducing its bond holdings and may soon need to expand its balance sheet through bond purchases. Williams said: "The next step in our balance sheet strategy will be to assess when reserve levels move from currently slightly above ample to ample." He added that once this occurs, "it will be time to initiate a gradual asset purchase process."
Williams also stated: "Based on the recent persistent pressures in the repo market and other signs indicating that reserves are shifting from ample to slightly above ample, I expect we will soon reach an ample level of reserves." Some analysts expect the Fed may begin expanding its asset holdings through bond purchases in the first quarter of next year. Williams warned that it is difficult to pinpoint the exact timing. "I am closely monitoring various market indicators related to the federal funds market, repo market, and payments to help assess the state of reserve demand." He also cautioned that maintaining appropriate liquidity through bond purchases is not a stimulus measure. (Golden Ten Data)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.
Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.

WTI Price Forecast: Slides further below $100.50; bullish potential seems intact
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

